周三（8月13日）盘后，生物制药公司Insmed（INSM）股价大涨5.77%。引发投资者热情的是该公司重磅新药获得美国食品药品监督管理局（FDA）批准上市的消息。
FDA批准了Insmed公司的口服药物Brinsupri用于治疗非囊性纤维化支气管扩张症，这是首个获批用于该适应症的药物。支气管扩张症是一种以气道受损、持续咳嗽和粘液分泌过多为特征的慢性肺病。这一批准被视为Insmed公司的重大突破。
多家券商对此利好消息做出积极反应。杰富瑞证券将Insmed的目标价从129美元上调至148美元；瑞穗证券将目标价从130美元上调至165美元；加拿大皇家银行将目标价从120美元上调至138美元。分析师普遍认为，这款新药的获批将为Insmed带来可观的销售增长。
RBC Capital Markets分析师表示，此次批准是"最好的情况"，两种剂量均获批准，无重大警告。摩根大通预计，到2033年，Brinsupri的年销售额有望突破70亿美元。这些乐观预期推动了Insmed股价的强势上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.